Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review [BICR] per modified Response Assessment in Neuro-Oncology [RANO] 2.0), and are not in need of immediate chemotherapy or radiotherapy.
調査の概要
状態
条件
介入・治療
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Clinical Trials at Nuvation Bio
- 電話番号:332-208-6102
- メール:ClinicalTrials@nuvationbio.com
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90095
- まだ募集していません
- University of California, Los Angeles
-
主任研究者:
- Robert Chong, MD
-
コンタクト:
- Quan Li
- 電話番号:310-825-1416
- メール:quanli@mednet.ucla.edu
-
San Francisco、California、アメリカ、94143
- まだ募集していません
- University of California, San Francisco
-
主任研究者:
- John De Groot, MD
-
コンタクト:
- Neuro Onc New Patient Coordinator
- 電話番号:415-353-2193
- メール:neurooncnewpatientcoord@ucsf.edu
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06510
- まだ募集していません
- Yale University
-
主任研究者:
- Nicholas Blondin, MD
-
コンタクト:
- Amy Rodrigues
- メール:amy.rodrigues@yale.edu
-
コンタクト:
-
-
Florida
-
Miami、Florida、アメリカ、33136
- まだ募集していません
- University of Miami Health
-
コンタクト:
- Leonela Wright
- 電話番号:305-243-0864
- メール:lxw612@med.miami.edu
-
主任研究者:
- Juan Blaquier, MD
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- 募集
- Indiana University
-
主任研究者:
- Kathryn Nevel, MD
-
コンタクト:
- NeuroOncology Clinical Trials
- 電話番号:3179634823
- メール:neuroct@iu.edu
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70112
- まだ募集していません
- LSU LCMC Health Cancer Center
-
主任研究者:
- Yazmin Odia, MD
-
コンタクト:
- Yazmin Odia
- 電話番号:(646) 634-9655
- メール:yodia@lsuhsc.edu
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02214
- まだ募集していません
- Massachusetts General Hospital
-
コンタクト:
- Vihang Nakhate
- 電話番号:617-724-8770
- メール:vnakhate@mgh.harvard.edu
-
主任研究者:
- Vihang Nakhate, MD
-
-
New Jersey
-
New Brunswick、New Jersey、アメリカ、08901
- まだ募集していません
- Rutgers Cancer Institute
-
主任研究者:
- Morana Vojnic, MD
-
コンタクト:
- Kasie Diorio
- 電話番号:732-235-2465
- メール:kassie.diorio@rutgers.edu
-
-
New York
-
New York、New York、アメリカ、10016
- 募集
- NYU Langone Health
-
コンタクト:
- Jose McFaline-Figueroa, MD
- 電話番号:212-731-6267
- メール:Jose.McFalineFigueroa@nyulangone.org
-
New York、New York、アメリカ、10032
- まだ募集していません
- Columbia University Medical Center
-
主任研究者:
- Andrew Lassman, MD
-
コンタクト:
- Research Nurse Navigator
- 電話番号:212-342-5162
- メール:Cancerclinicaltrials@cumc.columbia.edu
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- まだ募集していません
- Cleveland Clinic
-
主任研究者:
- Mina Lobbous, MD
-
コンタクト:
- Marci Ciolfi
- 電話番号:216-445-3307
- メール:ciolfim@ccf.org
-
Columbus、Ohio、アメリカ、43210
- まだ募集していません
- The Ohio State University Comprehensive Cancer Center
-
コンタクト:
- Pierre Giglio
- 電話番号:614-293-4448
- メール:Pierre.Giglio@osumc.edu
-
主任研究者:
- Pierre Giglio, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1p19q co-deleted oligodendroglioma, according to WHO CNS 2021 criteria
- IDH1 mutation (e.g., R132H/C/G/S/L) based on immunohistochemistry (IHC) (R132H only), PCR, or next generation sequencing (NGS).
- Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection).
- Measurable disease per modified RANO 2.0 confirmed by BICR during Screening.
- Previously treated with vorasidenib and experienced radiographic disease progression during treatment and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator. Disease progression must be confirmed by BICR using modified RANO 2.0.
- Adequate hematologic and organ function
- Expected survival of ≥12 months
Key Exclusion Criteria:
- Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) and vorasidenib for treatment of glioma.
- Discontinued vorasidenib for toxicity or any reason other than radiographic disease progression
- Prior treatment with anti-angiogenic agents such as Avastin (bevacizumab) or investigational agents for glioma.
- Brainstem or spinal cord involvement either as primary location, site of multifocal involvement, or by significant tumor extension.
- Significant functional or neurocognitive deficits, including uncontrolled seizures
- Evidence of leptomeningeal disease.
- Use of therapeutic doses of steroids for signs/symptoms of glioma. Participants taking physiologic doses (defined as equivalent of <1.5 mg of dexamethasone equivalent) for medical conditions not related to glioma will be permitted.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Safusidenib
Safusidenib 250 mg BID |
Safusidenib administered twice daily as a single agent orally on Days 1 to 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)
時間枠:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
ORR defined as the proportion of participants with the confirmed best overall response of Complete Response (CR), Partial Response (PR) or Minor Response (MR) per modified RANO 2.0, assessed by BICR |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
ORR per modified RANO 2.0 assessed by Investigator
時間枠:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
ORR defined as the proportion of participants with the confirmed best overall response of CR, PR or MR per modified RANO 2.0, assessed by the Investigator |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Volumetric Tumor Growth Rate (TGR) by BICR
時間枠:From historical scans through the final scan in the study, approximately 18 months
|
TGR defined as the percentage change in tumor volume by unit of time, assessed by BICR |
From historical scans through the final scan in the study, approximately 18 months
|
|
Duration of Response (DOR) per modified RANO 2.0 assessed by BICR and by Investigator
時間枠:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
DOR, time from the first documentation of objective response (CR, PR, or MR) to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier. |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Time to Next Intervention (TTNI)
時間枠:From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
|
TTNI, defined as the time from the first dose of study drug to the initiation of first subsequent anticancer therapy or death from any cause, whichever occurs earlier |
From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
|
|
Progression Free Survival (PFS) per modified RANO 2.0 assessed by BICR and by Investigator
時間枠:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
PFS, defined as the time from the first dose of study drug to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier. |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Time to Response (TTR) per modified RANO 2.0 assessed by BICR and by Investigator
時間枠:From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
|
TTR, defined as the time from the first dose of study drug to the first documentation of objective response (CR, PR, or MR) per modified RANO 2.0, assessed by BICR and by the Investigator |
From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
|
|
Overall Survival (OS)
時間枠:From the date of first dose of study drug until the date of death, approximately 18 months
|
OS, defined as the time from the first dose of study drug to death from any cause. |
From the date of first dose of study drug until the date of death, approximately 18 months
|
|
Safety and tolerability
時間枠:From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
|
The safety and tolerability of safusidenib evaluated based on AEs graded by NCI-CTCAE version 5.0, laboratory abnormalities as graded by NCI-CTCAE version 5.0, vital signs, physical examinations, and ECGs |
From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
|
|
Seizure Activity
時間枠:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
Evaluate seizure frequencies and severity including type of seizure, seizure-related AEs, and changes in anti-epileptic medications in participants receiving safusidenib |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NUV-218-G209
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。